Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

Table 1

Summary of clinical parameters before and after administration of Lactobacillus Brevis CD2 or placebo lozenges.

		Lactobacillus brevis CD2 (𝑛=15)					Placebo (𝑛=15)					Intergroup comparison
		Severe (𝑛)	Moderate (𝑛)	Mild (𝑛)	Absent (𝑛)	Total Value	Severe (𝑛)	Moderate (𝑛)	Mild (𝑛)	Absent (𝑛)	Total value
Burning	before	7	5	3	0	34	8	4	3	0	35	𝑃=.9
	after	0	0	1	14	1	2	4	2	7	16	𝑃=.03
Spontaneous pain	before	6	6	3	0	33	7	5	3	0	34	𝑃=na
	after	0	0	1	0	1	3	4	1	7	18	𝑃=.02
Caused pain	before	9	6	0	0	39	10	5	0	0	40	𝑃=na
	after	0	0	1	14	1	5	2	1	7	20	𝑃=.02
Perilesional erythema	before	6	7	2	0	34	7	5	3	0	34	𝑃=NA
	after	0	0	1	0	1	3	4	1	7	18	𝑃=.02

Value assignment: 0: absent, 1: mild, 2: moderate, and 3: severe.